HSBC noted that Illumina is losing its market dominance, with declining instrument placements in the low-to-mid throughput ...

Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study1,2 DLBCL—an ...

Investing.com -- Roche (SIX:RO) on Thursday said it expects high single-digit growth in core profit for 2025, following a strong performance in 2024 driven by strong sales in both ...

罗氏控股ADR (RHHBY) (ISIN: US7711951043)股票专题，提供今日罗氏控股ADR(RHHBY) (ISIN: US7711951043)股票最新股价查询，实时市场行情，走势图表，及罗氏控股公司ADR(RHHBY) (ISIN: US7711951043)股票的专业技术分析，投资者论坛，历史交易数据，最新消息和未来价格预测。 罗氏 ...

In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Hold rating on Roche Holding AG (RHHVF – Research Report), with a ...

Roche's Q4 results and innovative advancements make it a strong pick. Its late-stage pipeline supports our belief that there ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

J.P. Morgan analyst Richard Vosser maintained a Sell rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of ...

Roche's innovative sequencing by expansion (SBX) technology represents a leap forward in next-generation sequencing (NGS), ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...

Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries Evrysdi tablet can be stored at room temperature and offers the same demonstrated efficacy and ...